The BAFFling effects of rituximab in lupus: danger ahead?
- 18 February 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 12 (6), 367-372
- https://doi.org/10.1038/nrrheum.2016.18
Abstract
Suboptimal trial design and concurrent therapies are thought to account for the unexpected failure of two clinical trials of rituximab in patients with systemic lupus erythematosus (SLE). However, in this Opinion article we propose an alternative explanation: that rituximab can trigger a sequence of events that exacerbates disease in some patients with SLE. Post-rituximab SLE flares that are characterized by high levels of antibodies to double-stranded DNA are associated with elevated circulating BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B or BLyS) levels, and a high proportion of plasmablasts within the B-cell pool. BAFF not only perpetuates autoreactive B cells (including plasmablasts), particularly when B-cell numbers are low, but also stimulates T follicular helper (TFH) cells. Moreover, plasmablasts and TFH cells promote each others' formation. Thus, repeated rituximab infusions can result in a feedback loop characterized by ever-rising BAFF levels, surges in autoantibody production and worsening of disease. We argue that B-cell depletion should be swiftly followed by BAFF inhibition in patients with SLE.Keywords
This publication has 68 references indexed in Scilit:
- B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1The Journal of Experimental Medicine, 2012
- Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiationThe Journal of Experimental Medicine, 2012
- Resolve, revise, and relax: The 3 Rs of B cell repertoire adjustmentImmunology Letters, 2012
- Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T CellsImmunity, 2012
- B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levelsRheumatology, 2012
- BAFF and selection of autoreactive B cellsTrends in Immunology, 2011
- BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretionCellular Immunology, 2010
- Follicular helper T cells are required for systemic autoimmunityThe Journal of Experimental Medicine, 2009
- Blood Dendritic Cells Interact with Splenic Marginal Zone B Cells to Initiate T-Independent Immune ResponsesImmunity, 2002
- DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002